|

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

RECRUITINGPhase 3Sponsored by Elisabethinen Hospital
Actively Recruiting
PhasePhase 3
SponsorElisabethinen Hospital
Started2024-01-11
Est. completion2025-12-31
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06391892

Summary

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Informed consent
* \>18 years old
* localized pancreatic cancer to go for upfront surgery

Exclusion Criteria:

* synchronous secondary malignancy
* pregnancy

Conditions4

CancerCirculating Tumor CellPancreatic CancerPredictive Cancer Model

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.